A New Therapeutic Approach for Improving Dementia of the ALZHEIMER TYPE

Footnotes:

1. Franssen, EH, Reisberg, B, Kluger, A, Sinaiko, E, Conrado, B. Cognition-independent neurological symptoms in normal aging and probable Alzheimer’s disease. Arch Neurol 1991; 48: 148-654.
2. Reisberg, B, Ferris, SH, Kluger, A, Franssen, E, De leon, MJ, Mittelman, M, Borenstein, J, Rameschwar, K, Alba, R. Symptomatic changes in CNS aging and dementia of the Alzheimer type; cross-sectional, temporal and remediable concomitants. In: Bergener ?, Reisberg B. eds, Diagnosis and Treatment of Senile Dementia. Berlin, Springer-Verlag 1989: 193-223.
3. McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan, EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939-44.
4. Kopelman, MD. The cholinergic neurotransmitter system in human memory and dementia. Q J Exp Psychol 1986; 38A: 535-73.
5. Finch CE. Catecholamine metabolism in the brains of aging male mice. Brain Res 1973; 52: 261-76.
6. Finch CE. The regulation of physiological changes during mammalian aging. Q Rev Biol 1976; 51: 49-83.
7. Algeri S, Calderini G, Lomuscio G, Toffano G, Ponzio F. Catecholamines and adaptive mechanisms in senescent rats. In: Corsini GU, Gessa, L, eds. Apomorphine and other Dopaminomimetics. Vol. 2, Clinical Pharmacology, New York, Raven Press, 1981; 2: 225-34.
8. McGeer EG, McGeer PL, Wada SA. Distribution of tyrosine hydroxylase in human and animal brain. J Neurochem 1971; 18: 1647-51.
9. Nies A, Robinson DS, Davis JM, Ravaris CL. Changes in monoamine oxidase with aging and depression in man. In: Eisdorfer C, Fann WE eds. Psychopharmacology and Aging: Advances in Behavioral Biology. New York: Plenum Press, 1973: 41-52.
10. Carlsson A, Winblad B. Influence of age and time interval between death and autopsy of dopamine and 3-methosytyramine levels in human basal ganglia. J Neurol Transm 1976; 38: 271-301.
11. Gottfries CG, Gottfries L, Roos BE. Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and Parkinsonism. J Neurochem 1969; 16: 1341-5.
12. Gottfries CG. The metabolism of monoamines and their etiological importance in aging and in patients with dementia of Alzheimer type. In: Senile dementia: Outlook for the Future. New York: Alan R. Liss, Inc., 1984: 69-80.
13. Storga D, Vrecko K, Birkmayer JGD, Reibnegger G. Monoaminergic neurotransmitters in brains of morbus Alzheimer patients. Neurosci Lett (in print, 1966).
14. Reinikainen KJ, Soininen H, Riekkinen PJ. Neurotransmitter changes in Alzheimer’s disease: implications to diagnostics and therapy. Neurosci Res 1990; 27: 576-86.
15. Allard P, Alafuzoff I, Carlsson A. Eriksson K, Ericson E, Gottfries CG, Marcusson JO. Loss of dopamine uptake sites labeled with (3H) GBR-12935 in Alzheimer’s disease. European Neurol 1990; 30: 181-5.
16. Marcusson JO, Alafuzoff I, Bacstrom IT, Ericson E. Gottfries CG, Winblad B. 5-Hydroxytryptamine-sensitive 3 imipramine binding of protein nature in the human brain II, Effect of normal aging and dementia disorders. Brain Res 1987; 425: 137-45.
17. Pearce J. Mental changes in Parkinsonism. Brit. Med. J. Letter, 1974; 1: 445.
18. Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A. Oreland L, Svennerholm L, Winblad B. Parkinsonism and dementia disorders Alzheimer type: similarities and differences. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson’s Disease. Current Progress, Problems and Management. Amsterdam, Elsevier/North Holland Biomedical Press, 1980: 197-211.
19. Birkmayer JGD, Birkmayer W. Stimulation of endogenous L-DOPA biosynthesis. A new principle for the therapy of Parkinson’s disease. I. The clinical effect of nicotin amidadenin dinucleotide (NADH) and nicotinamideadenindinucleotidephosphate (NADPH). Acta Neurol Scand 1989; 26: 183-7.
20. Birkmayer W, Birkmayer JGD, Vrecko C, Paletta B, Reschenhofer E. Nicotinamide Adenine Dinucleotide (NADH) as Medication for Parkinson’s disease experience with 415 patients. New Trends Clin Neuropharmacol 1990; 4 :7-24.
21. Birkmayer JGD, Vrecko C, Volc D, Birkmayer W. Nicotinamide adenine dinucleotide (NADH). A new therapeutic approach to Parkinson’s disease. Comparison of oral and parenteral application. Acta Neurol Scand 1993; 87: Suppl. 146: 32-5.
22. Corbisier p, Remacle J. Involvement of mitochondria in cell degeneration. Europ J Cell Biol 1990; 51: 173-82.
23. Birkmayer W. Birkmayer JGD. Nicotinamidadenindinucleotide (NADH): The new approach in the therapy of Parkinson’s disease. Ann Clin Lab Sci 1989; 19: 38-43.
24. Birkmayer W, Birkmayer JDG, Vrecko C, Paletta B, Reschenhofer E, Ott E. Nicotinamide adenine dinucleotide (NADH) as medication for Parkinson’s disease. Experience with 415 Patients. New Trends Clin Neuropharmacol 1990; 4: 7-24.
25. Birkmayer W, Birkmayer JGD, Vrecko K, Paletta B. The clinical benefit of NADH as stimulator of Endogenous L-DOPA biosynthesis in Parkinsonian patients. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, eds. Advances in Neurology. Parkinson’s Disease: Anatomy, Pathology, and Therapy New York: Raven Press, 1990; 53: 545-9.
26. Vrecko K, Birkmayer JGD, Krainz J. Stimulation of dopamine biosynthesis in cultured PC 12 phaeochromocytoma cells by the coenzyme nicotinamide adenine dinucleotide (NADH). J Neural Transm 1993; 5: 147-56.
27. Folstein MF, Folstein SE, McHugh PR. Minimental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
28. Reisberg B, Ferris SH, De leon MJ, Crook T. The Global Deterioration Scale (GDS). Psychopharmacol Bull 1988; 24: 661-3.
29. Reisberg B, Ferris SH, Kluger A, Franssen E, De Leon MJ, Mittelman M, Borenstein J, Rameshwar K, ALBA ?. Symptomatic changes in CNS aging and dementia of the Alzheimer Type: cross-sectional, temporal, and remediable goncomitants. In: Bergener ?, Reisberg B, eds. Diagnosis and Treatment of Senile Dementia. Berlin, Springer-Verlag, 1989: 193-223.
30. Reisberg B, Ferris SH, De Leon MJ. Senile dementia of the Alzheimer type: diagnostic and differential diagnostic features with special reference to functional assessment staging. In: Traber J, GISPEN WH, eds. Senile dementia of the Alzheimer type, vol. 2. Berlin, Springer-Verlag, 1985; 2: 18-37.
31. Samson JC. The biological basis of phosphatidylserine pharmacology. Clin Trials J 1987; 24: 1-8

. . . go back to the Library